

AMENDMENT
U.S. Appln. No. 09/462,740

B¹ 2. (Amended) The transgenic [mammals] mammal as claimed in claim 1, [in which they express] expressing the human complement inhibitor (DAF/CD55) in [their] endothelial cells.

B² 3. (Twice Amended) The transgenic [mammals] mammal as claimed in claim 1, [in which they express] expressing the human complement inhibitor (DAF/CD55) in [their] endothelial cells of organs and tissues of the whole body.

B³ 6. (Twice Amended) The transgenic [mammals] mammal as claimed in claim 1, in which [they are] the mammal is a domestic or laboratory [animals] animal.

B⁴ 7. (Amended) The transgenic [mammals] mammal as claimed in claim 6, in which [they are] the mammal is a transgenic [pigs] pig or a transgenic [mice] mouse.

Add the following claim 8:

B⁵ --8. The transgenic mammal as claimed in claim 1 wherein the promoter is a part of Sequence ID No. 1 including bases 4498 to 5397, inclusive.--

REMARKS

Reconsideration is respectfully requested in view of Applicants' amendments and remarks herein.

At this time, Applicants have amended the claims to incorporate the subject matter of claims 4 and 5 into claim 1. Thus, the promoter is now that of Sequence ID No. 1 or a part thereof capable of promoting expression of the human complement inhibitor (DAF) CD55).